Repurposing pemafibrate to treat liver disease associated with metabolic disorders

FHS
July 10, 2024
7:20 pm

The University of Barcelona has led a study that suggests using the drug known as pemafibrate to treat liver disease associated with metabolic disorders, the most common liver pathology in the world, which affects one in four people.

Is shift work associated with depression and anxiety, and if so, does lifestyle mediate the associations?

Researchers discuss the contribution of lifestyle factors in depression and anxiety among shift workers

August 17, 2023

Virtual screening yields small molecules to enhance cancer immunotherapy

The process of identifying promising small molecule drug candidates that target cancer checkpoints may become faster and smarter through virtual screening, according to Weill Cornell

November 7, 2024

Ipsen joins the ADC club with deal worth up to $900m – Pharmaceutical Technology

Share this article Ipsen signed a deal with Sutro Biopharma for ADC development. Credit: HJBC via Shutterstock Ipsen has joined the slew of companies developing

April 2, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.